Sponsored satellite symposia 

9:00-10:30 Sponsored satellite symposium 1 AstraZeneca

Illuminating a new pathway in breast cancer

09:00 The guiding light – meeting the needs of the patient
09:05 Welcome and introduction
09:10 Highlighting a new target in breast cancer – DNA damage response
09:25 Shining the light on a new breast cancer paradigm
09:35 Opportunity for questions
09:45 PARP inhibitors – a spark for change in breast cancer management
10:05 In the spotlight – the use of BRCA in clinical practice
10:15 Opportunity for questions
10:25 Summary and close

Symposium faculty:
Cristina Cruz, Institute of Oncology, Barcelona, Spain
Pierfranco Conte, Istituto Oncologico Veneto, Padova, Italy
Christian Jackisch, Sana Klinikum Offenbach, Offenbach, Germany
Sibylle Loibl, German Breast Group, Neu-Isenburg, Frankfurt, Germany

11:00-12:30 Sponsored satellite symposium 2 Novartis
Patient-centric treatment decisions in clinical practice: Harnessing the power of combination therapy

11:00 Joining forces for efficacy: The current state of targeted therapy for HR+, HER2– advanced breast cancer (Chair: Luis Costa, PT - Diana Luftner, DE)
11:15 Patterns, combinations, and sequences: Case-based discussion on treatment decisions for HR+,
HER2– advanced breast cancer (Case Presenter and Moderator: Diana Lüftner, DE; Panelists: Luis Costa, PT - Guenther Steger, AT)
12:10 Q & A discussion (Moderator: Guenther Steger, AT)
12:20 Forging future understandings (Chair: Luis Costa, PT)

Symposium faculty:
Luis Costa, Hospital Santa Maria, Lisbon, Portugal
Diana Lüftner, Humboldt University, Berlin, Germany
Guenther Steger, Medical University of Vienna, Vienna, Austria

18:00-19:30 Sponsored satellite symposium 3 Pfizer Oncology
A united vision for mBC: Changing the treatment paradigm with CDK4/6 inhibitors

Chair: Michael Gnant, AT

18:00 Welcome and introduction (Michael Gnant, AT)

18:10 A united vision for HR+ HER2– mBC: The Global Decade Report (Speaker to be announced)

18:30 Q&A (Speaker to be announced)

18:35 Challenging current perceptions in HR+/HER2– mBC (Sibylle Loibl, DE)

18:55 A glimpse into the therapy management of CDK4/6 inhibitors (Johannes Ettl, DE)

19:15 Panel discussion and Q&A (All faculty)

19:25 Closing remarks (Michael Gnant, AT)

Symposium faculty:
Johannes Ettl, Technical University of Munich, Munich, Germany
Michael Gnant, Medical University of Vienna, Vienna, Austria
Sibylle Loibl, German Breast Group, Neu-Isenburg, Frankfurt, Germany


18:00-19:30 Sponsored satellite symposium 4 Celgene


The evolving sequence of therapies, moving forward in mBC: All chemotherapies are not created equally

(Chair: Grazia Arpino, IT)

18:00 Welcome and objectives (Grazia Arpino, IT)
18:10 Interactive patient case series: Improving how we manage patients with mBC (Frederik Marme, DE
Marina Cazzaniga, IT - Eva Ciruelos, ES)
• Indolent mBC: Are we making optimal use of all our treatment options?
• Rapidly progressive mBC: Identifying the correct treatment sequence in these challenging patients
• Treating triple negative mBC: Clinical considerations for the use of Abraxane
19:00 Improving disease outcomes in patients with mBC: Choosing the right algorithm
(Panel and audience discussion of the patient case study series)
19:25 Summary and close (Grazia Arpino, IT)

Symposium faculty:
Grazia Arpino, University of Naples Federico II, Italy
Marina Cazzaniga, San Gerardo Hospital, Monza, Italy
Eva Ciruelos, University Hospital 12 de Octubre, Madrid, Spain
Frederik Marme, Universität Heidelberg, Heidelberg, Germany